Newsfeeds - Spark Newswire

2 minute read

FDA
News

ImmunityBio Says Co Meets Primary Endpoint In Second Indication In Bladder Cancer Trial With 57% Disease-Free Survival In Patients With BCG Unresponsive Papillary Disease

Today, 9:21 PM

ImmunityBio , a clinical-stage immunotherapy company, today announced that Papillary disease (Cohort B), the second indication of its QUILT 3.032 Phase 2/3 study of intravesical BCG plus Anktiva in patients with

IBRX

2 minute read

FDA
News

ImmunityBio Completes Enrollment In Phase 2 Study Of Nant Cancer Vaccine For 3rd Line Or Greater Metastatic Pancreatic Cancer Patients; Says 90% of Patients Have Exceeded Historical Survival Rates To Date

By Benzinga Newsdesk

Today, 9:21 PM

ImmunityBio, Inc. ((http://www.w3.org/1999/xhtml" rel="nofollow"

IBRX

2 minute read

ImmunityBio Reports Lung-MAP Public-Private Partnership With Study Co.’s IL-15 Receptor Superagonist Complex In Trial

By Benzinga Newsdesk

Today, 9:21 PM

Lung-MAP trials are studying how well investigational or new drugs work in non-small cell lung cancer (NSCLC) patients and will study how N-803 (Anktiva) could bolster the current standard of care, checkpoint

IBRX

3 minute read

ImmunityBio Announces Updated Data From Ongoing Bladder Cancer Trial Showing Complete Response Rate Of 72%

By Bill Haddad

Today, 9:21 PM

58 out of 81 (72%) patients achieved a complete response at any time (three or six months), which compares favorably to historical complete response rates of 41% and 18% for FDA-approved therapies

IBRX

4 minute read

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test

By Shanthi Rexaline

Today, 9:21 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)

ABSI

1 minute read

Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg

By Vandana Singh

Today, 9:21 PM

Johnson & Johnson (NYSE:JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used…

AZN

3 minute read

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week

By Shanthi Rexaline

Today, 9:21 PM

Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.

AFMD